Healthcare CRO Services Market by Type, Therapeutic Area, and End-User : Global Opportunity Analysis and Industry Forecast, 2019–2026

March 2020 •
182 pages •
Report ID: 5897545 •
Format: PDF

Summary
Table of contents

Healthcare CRO Services Market by Type (Early Phase Development, Clinical Development Services, Laboratory Services, and Consulting Services), Therapeutic Area (Oncology, CNS Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Diabetes, and Others), and End-User (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, and Academic Institutes): Global Opportunity Analysis and Industry Forecast, 2019–2026

The global healthcare contract research organization (CRO) services market was valued at $38,996.9 million in 2018 and is expected to reach $66,036.6 million by 2026, registering a CAGR of 6.9% from 2019 to 2026. Contract research organizations (CROs) are outsourcing companies or groups that conduct specific and focused R&D clinical trials for the pharmaceutical or biotech industry. They possess well-experienced professionals that offer preclinical, clinical, and regulatory activities for drug and medical devices development, and their commercialization. These organizations can range from international full-service groups to small or niche service providing groups. In addition, CROs provide the experience of moving a novel drug, molecule, or a drug from its nascent phase to marketing approval, without any involvement of a sponsor for these services.

Surge in R&D for the development of novel drugs and medical devices and rise in healthcare expenditure are the major factorsthat drive the market growth. Moreover, CROs help in saving time and extra cost of manufacturers as it reduces the time to conduct a trial compared to the time taken for doing the same trials in-house, whichleadsto significant cost savings. However, penetrating competition in the market and dearth of skilled professionals are the major factors anticipated to hamper the market growth. Moreover, rise in the biotech and pharmaceutical sector in developing economies is expected to create lucrative opportunities for the market.

The market is segmented on the basis of service type, therapeutic area, end-users, and region. By service type, it is categorized into early phase development, clinical development services, laboratory services, and consulting services. By therapeutic area, it is segmented into oncology, CNS disorder, cardiovascular disease, metabolic disease, infectious disease, diabetes, and others. By end-users it is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Service Type
• Early Phase Development
• Clinical Research Services
• Laboratory Services
• Consulting Services

By Therapeutic Area
• Oncology
• CNS Disorder
• Cardiovascular Disease
• Metabolic Disease
• Infectious Disease
• Diabetes
• Others

By End-User
• Pharmaceutical Companies
• Medical Device Companies
• Academic Institutes

By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
• IQVIA
• PRA Health Sciences
• ICON
• Syneos Health
• Evotec
• Charles River
• Medpace
• Labcorp
• Biotelemetry
• Syngene

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

FAQ

Testimonials

The market research advisor answered my questions quickly and professionally. ReportBuyer's team did their best to ensure that I felt comfortable before making the investment to purchase the report.

Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

My overall experience with ReportBuyer today has been very positive, and I must thank you for your patience (...). Also, the sample you sent me and the explanations provided were very helpful.

D. Lescuyer

Executive Vice President Oral Business at Skyepharma

The research specialist was very helpful, and proposed the best content for my needs. ReportBuyer also offered a great follow-up, thanks for everything !

P. Thompson

EMEA Managing Director

We were satisfied with the support that ReportBuyer's team provided. Thanks to their recommendations, the report we purchased provided exactly what we want.

Y. Wang

Business Analyst

We didn't have time to do the research internally, and thanks to ReportBuyer's team we were able to find the appropriate data.

S. Chen

Research Coordinator

I was impressed by the customer service: it was fast, responsive, and 100% professional !

D. Krivan

Market Research Analyst

The research specialist provided prompt and helpful service. He also followed up to ensure I had all the information to deliver my business development plan.

C. Adams

Senior Business Development Manager